Much ADaM about nothing

By Endri   Hale Rowland  

Pharmaceutical Programming, Vol. 4, Iss. 1-2, 2011-12 ,pp. : 45-50

Maney Publishing

Access to resources Recommend Favorite

British Biotech: how much value is there in metalloproteinase inhibitors?

By Thomas S.M.   Falkenherr R.   Burke J.F.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 7, 1997-07 ,pp. : 687-693

Informa Healthcare

Access to resources Recommend Favorite

Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development

By Engelsman John   Garidel Patrick   Smulders Ronald   Koll Hans   Smith Bryan   Bassarab Stefan   Seidl Andreas   Hainzl Otmar   Jiskoot Wim  

Pharmaceutical Research, Vol. 28, Iss. 4, 2011-04 ,pp. : 920-933

Springer Publishing Company

Access to resources Recommend Favorite

Adenosine in the mammalian heart: nothing to get excited about

By Pelleg A.   Kutalek S.P.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 7, 1997-07 ,pp. : 236-238

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects

By  

Pharmacology Research & Perspectives, Vol. 6, Iss. 1, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite